Quantcast

Latest Perrigo Stories

2014-08-13 16:25:30

DUBLIN, Aug. 13, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.105 per share, payable on September 16, 2014 to shareholders of record on August 29, 2014. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo...

2014-07-31 08:36:33

DUBLIN, July 31, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its fourth quarter and fiscal year 2014 on Thursday, August 14, 2014 at approximately 8:00 a.m. (ET). The Company will conduct a conference call at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and Chief Executive Officer. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO The conference call will be available live...

2014-07-30 08:33:18

DUBLIN, July 30, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for desoximetasone topical spray 0.25% and that it has notified Taro Pharmaceuticals U.S.A., Inc., the owner of the Reference Listed Drug of its filing. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO On July 28, 2014, Taro filed suit against Perrigo in the United States District Court for...

2014-07-24 12:28:04

DUBLIN, July 24, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration (FDA) for its previously approved New Drug Application (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to [AbbVie's] AndroGel 1% and can be substituted with the full expectation that it will produce the same clinical effect and safety...

2014-07-08 08:31:53

DUBLIN, July 8, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil(®) Congestion Relief Tablets, 200 mg/10 mg. Perrigo expects to begin shipments of the product prior to the upcoming cough/cold/flu season....

2014-06-20 08:24:13

DUBLIN, June 20, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) and its partner, Catalent, announced today that they have settled their first to file Hatch Waxman litigation with Teva with respect to a generic version of Proair® HFA. Pursuant to the settlement, Perrigo has a limited quantity license to launch a generic version of Proair® HFA starting on December 19, 2016 (or earlier in certain circumstances) and an unlimited quantity license beginning after June 30,...

2014-06-03 12:31:25

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:World OTC Pharmaceutical Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/world_otc_pharmaceutical_market_2012_2022.html Report DetailsDiscover the highest potential revenues in over-the-counter medicineWhat does the future hold for OTC medicines? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and...

2014-05-30 08:25:22

DUBLIN, May 30, 2014 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the Jefferies 2014 Global Healthcare Conference on Monday, June 2, 2014 at 10AM ET at the Grand Hyatt Hotel in New York, NY. http://photos.prnewswire.com/prnvar/20120301/DE62255LOGO About Perrigo Company plc From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in...

2014-05-20 08:31:59

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding The Chubb Corporation (NYSE: CB), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), AstraZeneca Plc (NYSE: AZN), Mylan, Inc. (NASDAQ: MYL) and Perrigo Co. (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...

2014-05-13 16:28:39

TORONTO, May 13, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and nine month periods ended March 31, 2014. Selected Highlights Highlights for the Company during the nine month period ended March 31, 2014 and up to the date of this MD&A include the...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.